FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO
QUASAR Phase III study data show higher-dose aflibercept could reduce injection frequency for retinal vein occlusion patients. Bayer (Leverkusen, Germany)…
FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis
The designation aims to expedite development of ATSN-201 for X-linked retinoschisis, a rare inherited retinal disease with no approved treatment.The…
popular posts
latest posts
